#### REPROS THERAPEUTICS INC.

Form 8-K August 12, 2010

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

#### FORM 8-K

Current Report Filed Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 11, 2010

Repros Therapeutics Inc. (Exact name of registrant as specified in its charter)

Delaware 001-15281 76-0233274 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.)

2408 Timberloch Place, Suite B-7
The Woodlands, Texas 77380
(Address of principal
executive offices
and zip code)
(281) 719-3400
(Registrant's telephone
number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

[]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[] 240.14d-	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR -2(b))
[ ] 240.13e-	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 4(c))

#### Item 8.01 Other Events.

On August 11, 2010, Repros Therapeutics Inc. (the "Company") issued a press release titled "Repros Therapeutics Granted Key Patent for Androxal®." A copy of such press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

Number Description

99.1 Press Release dated August 11, 2010

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Repros Therapeutics Inc.

Date: August 12, 2010

By: /s/ Joseph S. Podolski Joseph S. Podolski

President and Chief Executive Officer

### **EXHIBIT INDEX**

Exhibit

Number Description

99.1 Press Release dated August 11, 2010